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Abstract
Background: Myoepithelial carcinoma of soft tissue is a rare, malignant neoplasm that is morphologically and
immunophenotypically similar to its counterpart in salivary gland. It demonstrates myoepithelial differentiation,
possessing both epithelial and myogenic characteristics. Thought to be chemotherapy insensitive, the optimal
treatment regimen of this tumor has yet to be established and only a select few cases in the literature discuss
treatment efficacy in detail.
Case presentation: Here we present a case of a young adult with metastatic myoepithelial carcinoma with an
initial excellent response to systemic therapy utilizing carboplatin and paclitaxel with continued complete response
after 3 years. The patient also underwent complete surgical excision and received adjuvant radiation to the primary
site of disease. Exome sequencing revealed an inactivating mutation in RB1 which we believe to be the first such
mutation to be reported in this cancer type.
Conclusions: Given increasing evidence suggesting RB1 loss is associated with responsiveness to conventional
chemotherapies, particularly platinum-based regimens, we hypothesize that this genetic feature predisposed
chemosensitivity in our patient’s tumor.
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Background
Myoepithelial tumors are rare salivary gland tumors
classically found in the parotid gland. Most are benign
myoepitheliomas. The malignant counterpart, myoe-
pithelial carcinoma, is even more rare and represents
less than 2% of salivary gland carcinomas [1]. Most cases
of myoepithelial carcinoma are de novo in origin but
may occasionally arise in association with a preexisting
myoepithelioma or benign mixed tumor (pleomorphic
adenoma) [2]. These malignant tumors also occur in
non-salivary sites, such the nasopharynx, lung, breast,
and skin [3–6]. About 50 cases of soft tissue locations of
this tumor, both benign and malignant, have been
described most often located in deep subcutaneous,
intramuscular, or subfascial tissue of the limbs and limb
girdles [1, 6–10]. Compared to their salivary equivalent
these tumors demonstrate increasing tendency for
metastasis as well as aggressive histologic features,
particularly within the pediatric population [1, 11].
These tumors exhibit a heterogenous histomorphology
and variable immunophenotypic findings, in turn, prov-
ing difficult to diagnosis [1]. Several recurrent molecular
underpinnings unique to soft tissue myoepithelial carcin-
oma have been described, including EWSR1 gene
rearrangements in up to 45% of cases [12]. Additionally,
homozygous deletion of SMARCB1 has been reported in
3/5 cases that lack the EWSR1 gene rearrangement [13].
Comprehensive molecular analysis of this rare tumor type,
however, has not been performed.
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Materials and methods
A chart review was conducted under IRB approval
(MCC15003, University of South Florida IRB). To
further evaluate our patient for a potential molecular
explanation for dramatic chemotherapy response, we
performed whole exome sequencing on the initial left
popliteal mass resection, prior to any radiation or
chemotherapy. Paired-end sequencing was performed on
Illumina NextSeq 500 (76 × 2) instrument, generating
214,044,758 total read pairs, resulting in 107× mean
coverage across the capture region after duplication
removal and mapping. 99.6% of targeted bases achieved
at least 10× depth of coverage. Burrows-Wheeler Aligner
was used to align sequence reads to the human reference
[14]. The Genome Analysis Toolkit was used for inser-
tion/deletion realignment, quality score recalibration,
and identification of single nucleotide and insertion/dele-
tion variants [15]. To enrich for somatic mutations, we re-
stricted our analysis to variants that are rare or absent in
population databases (MAF <0.01 in 1000 Genomes
Project, the NHLBI Exome Sequencing Project, and ExAC
database). To further limit our findings to those most
likely to be oncogenic, we utilized curated databases
including COSMIC and the Cancer Gene Census to
manually review variants for functional consequence and
known status as an oncogene/tumor suppressor gene.
Case presentation
A 34-year-old male presented to our institution for
evaluation of a left popliteal mass that was present and
growing over 1 year with increasing pain. There was no
neurologic or vascular compromise distal to the lesion.
The patient developed inguinal pain 1 month prior to
presentation. Otherwise the review of systems was
negative.
Left knee MRI demonstrated a large, lobulated nonspe-
cific T2-weighted hyperintense soft tissue mass in the
popliteal fossa with local mass effect and surrounding soft
tissue edema suspicious for soft tissue sarcoma (Fig. 1a).
Contrast-enhanced computed tomography of the chest,
abdomen, and pelvis performed for tumor staging demon-
strated evidence of necrotic left external iliac lymphaden-
opathy (Fig. 1b), along with a right lung mass and a
pulmonary nodule (Fig. 1c) most consistent with distant
metastatic disease.
Tumor cells obtained from CT-guided core biopsy of
the popliteal mass and then subsequently of the inguinal
lymph nodes showed a proliferation of rounded epitheli-
oid to spindle shaped cells with hyperchromatic nuclei
arranged in trabecular-like architecture within hyalinized
stroma. Ultimately, complete surgical resection of the
primary, popliteal site was performed. Immunohisto-
chemical evaluation revealed reactivity for vimentin,
CAM5.2 as well as focal reactivity for CKAE1/3, EMA
and synaptophysin. The tumor was negative for S-100,
desmin, chromogranin and CD45. Further immunohisto-
chemical analysis following external consultation revealed
pankeratin and focal EMA positivity while staining for
GFAP, calponin, p63, CD99, FLI-1, CD34, MUC-4, ERG
and TLE-1 was negative. Given the limited sample, the le-
sion was tentatively termed “atypical spindle and round
cell neoplasm, possibly myoepithelial in type” (Fig. 2a-f).
The patient underwent radical resection of the popliteal
mass with a positive margin allowing sufficient tissue to
confirm the diagnosis. Grossly, the tumor measured
9.0 × 7.8 × 5.0 cm and cut sections showed an encapsu-
lated, pale white, rubbery, lobulated mass. Histopatho-
logic examination revealed a lobulated, multinodular,
infiltrative malignant neoplasm composed of cellular
nodules of epithelioid tumor cells with hyperchro-
matic nuclei showing frequent mitoses arranged in a
trabecular fashion. Small proportions of the nodules
were hypocellular with tumor cells exhibiting less
nuclear atypia and more prominent myxoid stroma.
Tumor necrosis was present. The specimen was again sent
for consultation and the staining profile mirrored that of
the biopsy specimens, aside from focal desmin positivity.
Molecular analysis was notably negative for rearrange-
ment of EWSR1 (22q12) locus and rearrangement of SS18
Fig. 1 Radiologic presentation. Upon initial presentation, (a) axial MRI
(short tau inversion recovery/STIR) demonstrate a large lobulated soft
tissue mass within the popliteal fossa, (b) axial contrast-enhanced CT
images demonstrate bulky, necrotic left external iliac lymph nodes, and
(c) axial CT images demonstrate a dominant right lung mass and small
nodule consistent with pulmonary metastases
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(SYT; 18q11.2) locus. Additional molecular testing (FISH
analysis) performed revealed no rearrangement of NR4A3.
In view of the histomorphologic features and reactivity for
epithelial markers, a final diagnosis of high-grade myoe-
pithelial carcinoma was rendered both locally and by
outside consultation, although the immunophenotype was
not definitive in that regard.
Because of the systemic disease burden and limited
reported activity of traditional sarcoma chemotherapeutic
regimens, the case was discussed amongst medical and
pediatric oncologists within and outside our institution
without a clear consensus. We elected to treat with 3 cy-
cles of carboplatin and paclitaxel initially with an almost
immediate clinical response. Surveillance CT imaging of
the chest, abdomen and pelvis demonstrated decreased
size of iliac lymph nodes and pulmonary metastases
consistent with tumor response to neoadjuvant therapy
while MRI demonstrated surgical changes without clear,
active disease (Fig. 3a-d).
The patient underwent a completion lymphadenectomy
of the left superficial femoral and deep pelvic nodes with-
out evidence of residual tumor in 25 examined lymph
nodes. The patient received an additional 2 cycles of car-
boplatin and paclitaxel. Due to incomplete radiographic
response the patient underwent a wedge resection, which
also confirmed pathologic complete remission without
malignancy identified. Hemorrhage and areas containing
epithelioid macrophages with foamy and/or hemosiderin
laden cytoplasm along focal adjacent hyaline fibrosis were
seen. This was interpreted to be compatible with chemo-
therapy effect. The patient received adjuvant radiation
therapy with 2 Gy fractions ×33 doses to the popliteal
fossa. The patient remains in radiographic remission
36 months from completion of chemotherapy. Molecular
studies were undertaken to elucidate the mechanism
responsible for the durable response to systemic therapy.
Results
From whole exome sequencing, we identified 509 high-
confidence coding variants in our tumor specimen,
including 45 truncating (missense, frameshift, or splice
site) and 464 nonsynonymous. Of these, we identified 2
truncating mutations in well-described tumor suppressor
genes, RB1 and MED12. We additionally note several
Fig. 2 Histologic analysis of tumor specimen at (a) 10× and (b) 20× magnification demonstrates rounded epithelioid to spindle shaped cells arranged
in a trabecular-like fashion. (c) High power field demonstrates mitotic activity. (d) Bone formation is also noted. (e) Immunohistochemical analysis at
20× magnification reveals CKAE1/3 and CAM5.2 reactivity in addition to (f) focal EMA reactivity
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mutations of less clear oncogenic consequence, including
a truncating mutation in ITGA2, a possible tumor sup-
pressor, and a nonsynonymous mutation in PDGFRA that
has been reported in several cancer cases, but is also an
uncommon population polymorphism [16–18]. Further
description of these notable mutations is provided in
Table 1.
Discussion
We report an exceptional and sustained response to
chemotherapy in a young adult with myoepithelial car-
cinoma arising from the popliteal fossa with lymph node
and pulmonary metastasis. While it is difficult to identify
literature with a response rate for this rare malignancy
or with a denominator of non-responders, there are at
least case reports where chemotherapy regimens with
broad activity have been attempted. Two such reports
have shown either complete or partial response to
carboplatin/paclitaxel [5, 6]. Partial response in two
adult patients is briefly mentioned in a myoepithelial
tumor review from 2008, whereas a second report details
a patient with a metastatic vulvar mass. Diagnosis in this
case was made based upon immunohistochemical staining
profile, which similarly was notable for CAM5.2 and focal
CKAE1/3 reactivity. The patient was treated initially with
excision of the mass and bilateral inguinal lymph node
dissection followed by pelvic radiation, but a broad
chemotherapy regimen utilizing carboplatin and paclitaxel
was initiated after the development of pulmonary metasta-
sis. A complete pathologic response was noted and the
patient remained in complete remission over 3 years. An
additional study showed complete response to both ifosfa-
mide and melphalan in a patient with metastatic soft
tissue disease [19]. In this report, the patient initially pre-
sented with a tumor in their toe, which subsequently
recurred in the ipsilateral lower extremity following
radical disarticulation. Hyperthermic isolated limb perfu-
sion using tumor necrosis factor and melphalan was initi-
ated with a complete response. Pelvic metastases were later
noted, successfully treated with ifosfamide and radiation.
Chemotherapeutic response in the pediatric population is
similarly difficult to identify. In a series of 29 pediatric
patients with soft tissue myoepithelial carcinoma, approxi-
mately half received chemotherapy [1]. Of these, only one
patient demonstrated a clinical response, seen after multiple
cycles of doxorubicin and ifosfamide due to metastasis
following initial tumor excision. An additional series of 7
non-metastatic, pediatric patients reported favorable out-
comes following a regimen utilizing cisplatin with six
patients remaining without evidence of disease at a mean
follow-up of 2.5 years [20]. Three of the seven tumors had
EWSR1 rearrangement which was previously identified in
series where it was associated with superficial location
and more likely to be benign [12, 21]. Our sequen-
cing methodology would be unlikely to have detected
an EWRS1 structural variation but clinical testing as
mentioned above was negative.
Local surgical tumor excision with wide margins is
recommended for myoepithelial carcinoma of soft tis-
sues, although the optimal approach to treatment has
yet to be established [6]. The efficacy of radiation or
chemotherapy, either as an adjuvant therapy or in meta-
static disease, also has not been consistently demon-
strated [1, 6, 11]. As is common with rare malignancies,
there is a lack of consensus guidelines and multiple
options for care. In this case chemotherapy was incorpo-
rated because of the patients young age and metastatic
presentation, but there are likely many scenarios
whereby chemotherapy may be of benefit for patients
with a similar malignancy whereby chemotherapy may
not be considered. In fact, myoepithelial carcinoma is
currently incorporated into a cooperative group clinical





ITGA2 NM_002203:exon17:c.G2155 T:p.E719X -
PDGFRA NM_006206:exon5:c.C661T:p.L221F rs139913632
Fig. 3 Radiologic response to cisplatin and paclitaxel. a Axial MRI
demonstrates postoperative changes following surgical resection
of popliteal mass without evidence of residual disease. b Axial
contrast-enhanced CT images following neoadjuvant chemotherapy
demonstrate decreased size of left external iliac nodes, consistent
with response to therapy. On chemotherapy at (c) 1 month and (d)
4 months after presentation, both the right lung mass and nodule
have markedly improved consistent with response to therapy
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trial for soft tissue sarcomas as a chemotherapy resistant
tumor eligible only for the “non-chemotherapy cohort”
(NCT02180867).
Histologically, myoepithelial tumors often display a
variety of cellular morphologies, making identification and
diagnosis more difficult. The tumors may be composed
exclusively of a single cell type, but are more frequently
present as a combination of epithelioid, spindle cell, plas-
macytoid or clear cell types [9]. Immunohistochemical
staining serves as a key step in differentiating from similar
appearing tumors. Myoepithelial carcinomas are generally
positive for S-100, cytokeratin, epithelial membrane anti-
gen (EMA) and α-smooth muscle actin [9]. The differen-
tial diagnosis include carcinoma, melanoma, epithelioid
sarcoma, extraskeletal myxoid chondrosarcoma and chor-
doma. EWSR1 gene rearrangement is identified in only
50% of the soft tissue myoepithlelial carcinoma [22].
Using whole exome sequencing, we examined our
patient’s tumor for possible oncogenic variants that may
help elucidate a mechanism for chemotherapy sensitiv-
ity. Given that matched germline DNA was not available
for comparison, we expect many of variants uncovered
to be rare or private germline mutations or passenger
somatic mutations and therefore of little oncogenic con-
sequence. We were able to identify, however, truncating
mutations in RB1 and MED12 that are very likely to be
somatic oncogenic drivers in this patient given the well-
established role of these two genes as tumor suppressors
across multiple tumor types. To our knowledge, this is
the first description of inactivating mutation in either of
these two genes reported in this cancer type.
The retinoblastoma protein (RB1) is one of the most
frequently affected tumor suppressors across multiple
cancer histologies and plays a critical role in regulation
of cell cycle and apoptosis [23]. RB1 pathway deregula-
tion has been reported in various benign and malignant
salivary tumors, including malignant myoepithelioma
[24]. Interestingly, preclinical and clinical evidence in
multiple cancer types suggest that RB1 expressional loss
is associated with increased responsiveness to conven-
tional chemotherapies [23]. Additionally, a recent
genomic study in small cell lung cancer showed that
presence of RB1 inactivating mutation was highly pre-
dictive of good response to platinum-based chemother-
apy [25]. Childhood retinoblastoma, almost invariably
caused by either germline or somatic mutational inacti-
vation of RB1, is also highly responsive to platinum-
based chemotherapy [26]. Given this mounting evidence,
we hypothesize that RB1 mutation in our patient’s tumor
predisposed to chemosensitivity. In contrast, loss of the
RNA polymerase II mediator complex member MED12
has been shown to induce drug resistance, particularly
to tyrosine kinase inhibitor therapy, via activation of
transforming growth factor B receptor signaling [27].
In summary, we report a case of myoepithelial carcin-
oma with a RB1 inactivating mutation that experienced
a dramatic response to platinum-based chemotherapy.
We believe that our case adds to growing evidence
across multiple cancer types that RB1 loss is predictive
of chemosensitivity, perhaps in particular to platinum-
based regimens. Given the rarity of this tumor type, the
optimal systemic therapy approach is not well defined.
Further study should be undertaken to evaluate whether
RB1 loss is a recurring feature in this histology and
whether platinum-based chemotherapy is more broadly
effective in this tumor type outside of this case.
Conclusion
While formal recommendations are difficult to make
based on a case report, our review of the literature
would suggest that continued consideration for systemic
carcinoma therapy, more specifically with paclitaxel and
carboplatin, should be considered in myoepithelial
carcinoma patients presenting with stage 4 disease and
extremity primary locations.
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